Cellegy Cellegesic SPA Clears FDA; NDA Resubmission Planned For Q3 2004
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cellegy’s Special Protocol Assessment agreement with FDA for its anal fissure therapy Cellegesic allows the firm to use pain at three weeks as the primary endpoint for a confirmatory trial.